EA200301097A1 - Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды - Google Patents
Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозидыInfo
- Publication number
- EA200301097A1 EA200301097A1 EA200301097A EA200301097A EA200301097A1 EA 200301097 A1 EA200301097 A1 EA 200301097A1 EA 200301097 A EA200301097 A EA 200301097A EA 200301097 A EA200301097 A EA 200301097A EA 200301097 A1 EA200301097 A1 EA 200301097A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- vaccines
- tumors
- combinations
- active ingredient
- idiotypic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- 150000002270 gangliosides Chemical class 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Данное изобретение относится к области иммунологии и, более конкретно, к иммунотерапевтическим комбинациям, используемым для регуляции роста и/или пролиферации клеток опухолей. С использованием данного изобретения наблюдали терапевтическое действие против опухолей в результате комбинирования идиотипических вакцин, главным активным ингредиентом которых является антиганглиозидное антитело (Ab1), с идиотипическими вакцинами, главным активным ингредиентом которых является антиидиотипическое антитело (Ab2), полученное против антиганглиозидного антитела, или вакцин, главным активным ингредиентом которых является один или более ганглиозидов. Описаны комбинации этих вакцин, которые проявляют синергическое терапевтическое действие против опухолей. Описанные комбинации могут быть применены к пациентам в различных клинических состояниях опухолей, экспрессирующих ганглиозиды.Отчет о международном поиске был опубликован 2003.01.03.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2001008420010084A CU23007A1 (es) | 2001-04-06 | 2001-04-06 | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
PCT/CU2002/000002 WO2002081661A2 (es) | 2001-04-06 | 2002-04-08 | Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200301097A1 true EA200301097A1 (ru) | 2004-02-26 |
EA006936B1 EA006936B1 (ru) | 2006-06-30 |
Family
ID=40291118
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200301097A EA006936B1 (ru) | 2001-04-06 | 2002-04-08 | Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды |
EA200301098A EA006310B1 (ru) | 2001-04-06 | 2002-04-08 | Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200301098A EA006310B1 (ru) | 2001-04-06 | 2002-04-08 | Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей |
Country Status (37)
Country | Link |
---|---|
US (3) | US20050069535A1 (ru) |
EP (3) | EP1798243B1 (ru) |
JP (2) | JP2004528033A (ru) |
KR (3) | KR100946168B1 (ru) |
CN (3) | CN101054417B (ru) |
AR (2) | AR033123A1 (ru) |
AT (3) | ATE378356T1 (ru) |
AU (3) | AU2002308347B2 (ru) |
BG (2) | BG66304B1 (ru) |
BR (3) | BR0208676B1 (ru) |
CA (2) | CA2443372C (ru) |
CU (1) | CU23007A1 (ru) |
CZ (2) | CZ296276B6 (ru) |
DE (2) | DE60228561D1 (ru) |
DK (2) | DK1384726T3 (ru) |
EA (2) | EA006936B1 (ru) |
EC (2) | ECSP034787A (ru) |
ES (2) | ES2312610T3 (ru) |
HK (3) | HK1066818A1 (ru) |
HR (2) | HRP20030806B1 (ru) |
HU (2) | HU228105B1 (ru) |
IL (2) | IL158246A0 (ru) |
IS (2) | IS6965A (ru) |
MX (2) | MXPA03008739A (ru) |
MY (3) | MY137078A (ru) |
NO (2) | NO331533B1 (ru) |
NZ (2) | NZ528599A (ru) |
PE (1) | PE20020972A1 (ru) |
PL (2) | PL208109B1 (ru) |
PT (2) | PT1411064E (ru) |
SG (1) | SG161737A1 (ru) |
SI (2) | SI1411064T1 (ru) |
SK (2) | SK287783B6 (ru) |
UA (3) | UA75393C2 (ru) |
UY (2) | UY27243A1 (ru) |
WO (2) | WO2002081496A2 (ru) |
ZA (2) | ZA200307585B (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
KR20070108536A (ko) * | 2005-02-04 | 2007-11-12 | 수르벡 에이피에스 | 서바이빈 펩티드 백신 |
FI20055398A0 (fi) | 2005-07-08 | 2005-07-08 | Suomen Punainen Risti Veripalv | Menetelmä solupopulaatioiden evaluoimiseksi |
DK2594591T3 (en) * | 2005-08-11 | 2018-07-30 | Matossian Rogers Arpi | TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE |
ES2659114T3 (es) * | 2005-08-19 | 2018-03-13 | Wyeth Llc | Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8 |
ITFI20060163A1 (it) * | 2006-06-29 | 2006-09-28 | Menarini Internat Operations Luxembourg Sa | Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio |
TWI434855B (zh) * | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
WO2009104649A1 (ja) * | 2008-02-22 | 2009-08-27 | 片山化学工業株式会社 | 合成糖脂質含有リポソーム |
EP2166085A1 (en) | 2008-07-16 | 2010-03-24 | Suomen Punainen Risti Veripalvelu | Divalent modified cells |
TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9拮抗劑類 |
SI2406284T1 (sl) | 2009-03-10 | 2017-01-31 | Biogen Ma Inc. | Anti-bcma protitelesa |
TW201038286A (en) | 2009-04-01 | 2010-11-01 | Genentech Inc | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
CU23736A1 (es) * | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
US8163283B2 (en) * | 2009-09-03 | 2012-04-24 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
EP2663334A4 (en) * | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
EP2641916A1 (en) * | 2012-03-23 | 2013-09-25 | Centre National de la Recherche Scientifique (C.N.R.S) | Novel antibodies anti-sPLA2-IIA and uses thereof |
JP6433889B2 (ja) | 2012-06-15 | 2018-12-05 | ファイザー・インク | Gdf−8に対する改善された拮抗抗体およびその使用 |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
TWI697503B (zh) * | 2014-04-10 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途 |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
PL3310814T3 (pl) | 2015-06-16 | 2023-12-11 | F. Hoffmann-La Roche Ag | Humanizowane i wykazujące dojrzałe powinowactwo przeciwciała przeciwko FcRH5 i sposoby stosowania |
WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
EP3548071A4 (en) | 2016-11-30 | 2020-07-15 | OncoMed Pharmaceuticals, Inc. | METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2754206B2 (ja) * | 1987-11-17 | 1998-05-20 | メクト株式会社 | α2→3結合を認識するモノクローナル抗体 |
US6051225A (en) * | 1988-10-19 | 2000-04-18 | The Dow Chemical Company | Family of high affinity, modified antibodies for cancer treatment |
DK0586002T3 (da) * | 1992-08-18 | 2000-06-19 | Centro Inmunologia Molecular | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho |
JPH07101999A (ja) * | 1993-10-06 | 1995-04-18 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするdna塩基配列 |
US6063379A (en) * | 1993-12-09 | 2000-05-16 | Centro De Inmunologia Molecular | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
ES2166770T3 (es) * | 1993-12-09 | 2002-05-01 | Centro Inmunologia Molecular | Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos. |
CU22702A1 (es) * | 1997-10-21 | 2001-07-31 | Centro Inmunologia Molecular | Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen |
CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
-
2001
- 2001-04-06 CU CU2001008420010084A patent/CU23007A1/es unknown
-
2002
- 2002-04-05 AR ARP020101264A patent/AR033123A1/es not_active Application Discontinuation
- 2002-04-05 UY UY27243A patent/UY27243A1/es unknown
- 2002-04-05 MY MYPI20021228A patent/MY137078A/en unknown
- 2002-04-05 AR ARP020101263A patent/AR033122A1/es unknown
- 2002-04-05 MY MYPI20081190A patent/MY145703A/en unknown
- 2002-04-05 MY MYPI20021239A patent/MY157372A/en unknown
- 2002-04-05 UY UY27242A patent/UY27242A1/es not_active Application Discontinuation
- 2002-04-08 CA CA2443372A patent/CA2443372C/en not_active Expired - Fee Related
- 2002-04-08 CZ CZ20032641A patent/CZ296276B6/cs not_active IP Right Cessation
- 2002-04-08 AT AT02759752T patent/ATE378356T1/de active
- 2002-04-08 DK DK02759751T patent/DK1384726T3/da active
- 2002-04-08 NZ NZ528599A patent/NZ528599A/en not_active IP Right Cessation
- 2002-04-08 MX MXPA03008739A patent/MXPA03008739A/es active IP Right Grant
- 2002-04-08 SI SI200230660T patent/SI1411064T1/sl unknown
- 2002-04-08 ES ES02759751T patent/ES2312610T3/es not_active Expired - Lifetime
- 2002-04-08 PT PT02759752T patent/PT1411064E/pt unknown
- 2002-04-08 DE DE60228561T patent/DE60228561D1/de not_active Expired - Lifetime
- 2002-04-08 KR KR1020037012969A patent/KR100946168B1/ko not_active IP Right Cessation
- 2002-04-08 EP EP06076643A patent/EP1798243B1/en not_active Expired - Lifetime
- 2002-04-08 CN CN2007101021039A patent/CN101054417B/zh not_active Expired - Fee Related
- 2002-04-08 BR BRPI0208676A patent/BR0208676B1/pt not_active IP Right Cessation
- 2002-04-08 SG SG200506530-5A patent/SG161737A1/en unknown
- 2002-04-08 CN CNB028086309A patent/CN100349920C/zh not_active Expired - Fee Related
- 2002-04-08 NZ NZ528598A patent/NZ528598A/en not_active IP Right Cessation
- 2002-04-08 WO PCT/CU2002/000003 patent/WO2002081496A2/es active Application Filing
- 2002-04-08 PT PT02759751T patent/PT1384726E/pt unknown
- 2002-04-08 BR BR0208675-1A patent/BR0208675A/pt not_active IP Right Cessation
- 2002-04-08 EA EA200301097A patent/EA006936B1/ru not_active IP Right Cessation
- 2002-04-08 HU HU0401695A patent/HU228105B1/hu not_active IP Right Cessation
- 2002-04-08 EP EP02759752A patent/EP1411064B1/en not_active Expired - Lifetime
- 2002-04-08 JP JP2002579482A patent/JP2004528033A/ja active Pending
- 2002-04-08 US US10/473,978 patent/US20050069535A1/en not_active Abandoned
- 2002-04-08 EA EA200301098A patent/EA006310B1/ru not_active IP Right Cessation
- 2002-04-08 US US10/473,977 patent/US20040253233A1/en not_active Abandoned
- 2002-04-08 PL PL371937A patent/PL208109B1/pl unknown
- 2002-04-08 PE PE2002000283A patent/PE20020972A1/es not_active Application Discontinuation
- 2002-04-08 AU AU2002308347A patent/AU2002308347B2/en not_active Ceased
- 2002-04-08 SK SK1216-2003A patent/SK287783B6/sk not_active IP Right Cessation
- 2002-04-08 CZ CZ2003-2668A patent/CZ304424B6/cs not_active IP Right Cessation
- 2002-04-08 AT AT06076643T patent/ATE477279T1/de not_active IP Right Cessation
- 2002-04-08 ES ES02759752T patent/ES2296986T3/es not_active Expired - Lifetime
- 2002-04-08 JP JP2002580025A patent/JP4366080B2/ja not_active Expired - Fee Related
- 2002-04-08 SI SI200230766T patent/SI1384726T1/sl unknown
- 2002-04-08 WO PCT/CU2002/000002 patent/WO2002081661A2/es active IP Right Grant
- 2002-04-08 PL PL02371770A patent/PL371770A1/xx not_active Application Discontinuation
- 2002-04-08 BR BRPI0208675-1A patent/BRPI0208675B1/pt unknown
- 2002-04-08 CN CNB028084330A patent/CN1319991C/zh not_active Expired - Fee Related
- 2002-04-08 AU AU2002308348A patent/AU2002308348B2/en not_active Ceased
- 2002-04-08 AT AT02759751T patent/ATE406386T1/de active
- 2002-04-08 DE DE60223547T patent/DE60223547T2/de not_active Expired - Lifetime
- 2002-04-08 DK DK02759752T patent/DK1411064T3/da active
- 2002-04-08 CA CA2441845A patent/CA2441845C/en not_active Expired - Fee Related
- 2002-04-08 IL IL15824602A patent/IL158246A0/xx unknown
- 2002-04-08 EP EP02759751A patent/EP1384726B1/en not_active Expired - Lifetime
- 2002-04-08 HU HU0401355A patent/HU228106B1/hu not_active IP Right Cessation
- 2002-04-08 MX MXPA03008738A patent/MXPA03008738A/es not_active Application Discontinuation
- 2002-04-08 SK SK1226-2003A patent/SK287914B6/sk not_active IP Right Cessation
- 2002-04-08 KR KR1020037012938A patent/KR100863509B1/ko not_active IP Right Cessation
- 2002-08-04 UA UA2003108989A patent/UA75393C2/uk unknown
- 2002-08-04 UA UA2003108988A patent/UA76745C2/ru unknown
-
2003
- 2003-09-23 IS IS6965A patent/IS6965A/is unknown
- 2003-09-23 IS IS6964A patent/IS2701B/is unknown
- 2003-09-29 ZA ZA200307585A patent/ZA200307585B/en unknown
- 2003-09-30 EC EC2003004787A patent/ECSP034787A/es unknown
- 2003-09-30 EC EC2003004788A patent/ECSP034788A/es unknown
- 2003-10-01 ZA ZA2003/07679A patent/ZA200307679B/en unknown
- 2003-10-02 IL IL158246A patent/IL158246A/en not_active IP Right Cessation
- 2003-10-03 NO NO20034436A patent/NO331533B1/no not_active IP Right Cessation
- 2003-10-03 BG BG108228A patent/BG66304B1/bg unknown
- 2003-10-03 BG BG108227A patent/BG66293B1/en unknown
- 2003-10-03 NO NO20034437A patent/NO20034437L/no not_active Application Discontinuation
- 2003-10-06 HR HR20030806A patent/HRP20030806B1/xx not_active IP Right Cessation
- 2003-10-06 HR HR20030805A patent/HRP20030805B1/xx not_active IP Right Cessation
-
2004
- 2004-12-14 HK HK04109894A patent/HK1066818A1/xx not_active IP Right Cessation
-
2005
- 2005-04-01 HK HK05102752A patent/HK1070080A1/xx not_active IP Right Cessation
- 2005-12-20 UA UAA200512270A patent/UA86768C2/ru unknown
-
2007
- 2007-10-26 AU AU2007231687A patent/AU2007231687B2/en not_active Expired - Fee Related
- 2007-12-31 HK HK07114311.6A patent/HK1109160A1/xx not_active IP Right Cessation
-
2008
- 2008-08-07 KR KR1020087019420A patent/KR100919617B1/ko not_active IP Right Cessation
-
2009
- 2009-03-19 US US12/407,046 patent/US8758753B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200301097A1 (ru) | Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды | |
ATE476448T1 (de) | Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung | |
CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
CY1105221T1 (el) | Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
TR200102707T2 (tr) | AĞrì hafifletme, kemik kanseri terapisi ve kemik yzeyinin saĞlìklì tutulmasì iin kirelenmiç hedef dokulara ynelik radyum-223 hazìrlanmasì ve kullanìmì. | |
DE60226499D1 (de) | Verwendung von antikörpern gegen das muc18-antigen | |
DK0702563T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme | |
IN2012DN00313A (ru) | ||
CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
NO20013906D0 (no) | Fremgangsmater for behandling av tumorer og metastaser ved a bruke en kombinasjon av antiangiogeniske- og immunoterapier | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
DK1992695T3 (da) | Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf | |
DK1684770T3 (da) | Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
EA200300646A1 (ru) | Иммунотерапевтический набор для лечения опухолей | |
ATE514780T1 (de) | Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon | |
GB0102145D0 (en) | Substances | |
CY1108612T1 (el) | Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη ογκων που υπερεκφραζουν γαγγλιοσιδες | |
ATE286914T1 (de) | Verwendung von blockierenden anti-tsh-rezeptor- antikörpern bei der therapie von hyperthyreosen sowie monoklonale antikörper für eine solche verwendung | |
DE502004012439D1 (de) | Medikament und verwendung zur tumortherapie | |
AR027738A1 (es) | Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas | |
TH59159B (th) | สารรวมที่ใช้รักษาภูมิคุ้มกันสำหรับการบำบัดรักษาเนื้องอกที่แสดงแกงกลิโอไซด์ที่มากเกินไป | |
ATE490981T1 (de) | Criptospezifische antikörper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |